Document is current
Any future updates will be listed below
-
Authors
Liu, Nian
Yan, Mingjie
Tao, Qian
Wu, Jie
Chen, Jing
Chen, Xiang
Peng, Cong https://orcid.org/0000-0001-7104-5490
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01835041 at ClinicalTrials.govnct03504423 at ClinicalTrials.govDocuments that mention this clinical trial
Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
https://doi.org/10.1136/jitc-2023-007146
nct01832857 at ClinicalTrials.govDocuments that mention this clinical trial
Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
https://doi.org/10.1136/jitc-2023-007146
Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma
https://doi.org/10.1136/bmjopen-2023-073839
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study
https://doi.org/10.1200/jco.23.02659
Documents that mention this clinical trial
Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
https://doi.org/10.1136/jitc-2023-007146
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82073018)
National Natural Science Foundation of China (82073458)
National Natural Science Foundation of China (8213000715)
National Natural Science Foundation of China (82203024)
National Natural Science Foundation of China (82221002)
Program of Introducing Talents of Discipline to Universities (111 Project, No. B20017)
The science and technology innovation Program of Hunan Province (2021RC4013)
- License Information
